home / stock / xbit / xbit news


XBIT News and Press, XBiotech Inc. From 07/09/19

Stock Information

Company Name: XBiotech Inc.
Stock Symbol: XBIT
Market: NASDAQ
Website: xbiotech.com

Menu

XBIT XBIT Quote XBIT Short XBIT News XBIT Articles XBIT Message Board
Get XBIT Alerts

News, Short Squeeze, Breakout and More Instantly...

XBIT - Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech's Bermekimab in Advanced Cancer Patients

AUSTIN, Texas, July 09, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the Medical Research Council (MRC), part of UK Research and Innovation, has awarded funding to study bermekimab therapy in a Phase 2 multi-center study in advanced cancers. The MRC will provide fun...

XBIT - XBiotech Wins "Commercial Real Estate Award for Industrial Development" for its Headquarters in Austin, Texas

AUSTIN, Texas, June 26, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it is the recipient of the first place 2019 Commercial Real Estate Award for Industrial Development, chosen by the Austin Business Journal. XBiotech USA Inc. received the award for its integra...

XBIT - XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa

AUSTIN, Texas, June 25, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus...

XBIT - XBiotech Added to Russell 3000® Index

AUSTIN, Texas, June 11, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Company has been added to the preliminary list of the broad market Russell 3000 ®  Index, which will take effect after US market close on June 28, as part of the 2019 Russell indexe...

XBIT - Daily Insider Ratings Round Up 6/6/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

XBIT - XBiotech Announces Closing of Public Offering of Common Shares

AUSTIN, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced the closing of its previously announced underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share.  In addition, XBiotech has granted the und...

XBIT - NTNX, WSM and GCO among midday movers

Gainers:  Stellar Biotechnologies (NASDAQ: SBOT ) +55% . Genocea Biosciences (NASDAQ: GNCA ) +52% . Mmtec (NASDAQ: MTC ) +27% . Capital Senior Living Corporation (NYSE: CSU ) +18% . Genesco (NYSE: GCO ) +13% . Williams-Sonoma (NYSE: WSM ) +13% . GTx (NASDAQ: GTXI ) +12% . Charl...

XBIT - XBiotech Announces Pricing of Public Offering of Common Shares

AUSTIN, Texas, May 31, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced the pricing of an underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share.  The offering is expected to close on or about June 4, 2019, subject...

XBIT - XBiotech Announces Public Offering of Common Shares

AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions.   XBiotech intends to grant the underwriter in the offering a 30-day option ...

XBIT - XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidra...

Previous 10 Next 10